Medical Health & Life Science Research News

Asia Pacific's leukemia therapeutics industry is expected to reach $2.09 billion by 2021 with a CAGR of 11.2% scrutinized in new research

Asia Pacific's leukemia therapeutics industry is expected to reach $2.09 billion by 2021 with a CAGR of 11.2% scrutinized in new research

Asia Pacific Leukemia Therapeutics Industry to grow at a CAGR of 11.2% during 2016 to 2021 | Market Data Forecast

- Advertising -

According to the report Asia-Pacific Leukemia Therapeutics Industry, published by Market Data Forecast, The Asia Industry has been estimated at USD 1.23 Billion in 2016 and is projected to reach USD 2.09 Billion by 2021, at a CAGR of 11.2% during the forecast period from 2016 to 2021. 

Leukemia is the cancer of the white blood cells or the bone marrow, which occurs due to an abnormal increase in the count of white blood cells. There are several types of leukemia that appear suddenly and progress rapidly over days to weeks.

It can be identified by the spread of the diseases and by the type of the blood cell that is affected.

- Advertising -

Browse Market data tables and in-depth TOC of the Asia-Pacific Leukemia Therapeutics Industry to 2021 @ www.marketdataforecast.com/market-…utics-market-825/

The Industry for Leukemia Therapeutics in Asia-Pacific region is mainly driven due to factors like increasing aging population due to which there is an increasing occurrence of leukemia, along with increasing awareness of patients regarding most recent technological developments. But, the Industry growth is feared to drop due to high costs of drugs and therapies.

Asia-Pacific Industry for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the Industry is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia.

By diagnosis, the Industry is further sub-segmented into CT scan, biopsy and MRI. By treatments, the Industry is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy.

By drugs, the Industry is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic Industry owing to high prevalence rate.

Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic Industry. Gleevec was the one of the major Industry growth contributors, in the drugs category.

Free sample of the report is available @ www.marketdataforecast.com/market-…25/request-sample

Geographically, Asia-Pacific Industry for Leukemia Therapeutics is segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific Industry is growing at very high rate, due to rising consumer Industry, favorable government support for enhanced healthcare infrastructure, and rising awareness for healthcare among the population in developing nations of the region.

  1. Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited , Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Asia-Pacific Leukemia Therapeutics Industry.

Inquire report @ www.marketdataforecast.com/market-…arket-825/inquire

Key Points from Table of Contents

Overview                                                       

  • Executive Summary                                
  • Key Inferences                                         
  • New Developments                               

Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                    

Asia-Pacific Leukemia Therapeutics Industry: Segmentation

  • By Disease Condition                          
  • o Chronic Lymphatic Leukemia         
  • o Acute Lymphatic Leukemia             
  • o Chronic Myeloid Leukemia             
  • o Acute Myeloid Leukemia  
  • By Diagnosis                           
  • o CT scan    
  • o Biopsy      
  • o MRI          
  • By Treatments                        
  • o Chemotherapy     
  • o Radiation therapy
  • o Immunotherapy  
  • o Surgery    
  • o Targeted Therapy
  • o Bone marrow transplant  
  • o Stem Cell Therapy
  • By Drugs                    
  • o Gleevec    
  • o Sapacitabine         
  • o GA101      
  • o Vasaroxine            
  • o Tosedosat             

Geographical Analysis                                                              

  • China           
  • India            
  • Japan           
  • South Korea            

Strategic Analysis                                                       

  • PESTLE analysis                                                                       
  • Porter’s Five analysis                                              

Industry Leaders' Analysis                                                        

Competitive Landscape                                                           

Avail report @ www.marketdataforecast.com/market-…/request-discount

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...